doi:10.1016/j.cmet.2017.04.009
Your doctor will determine the appropriate dose based on your individual needs and medical conditions
The EMPA-REG and CANVAS trials showed that the SGLT-2i empagliflozin and SGLT-1/2i canagliflozin reduced the risk of MACE in T2D patients with or at high risk of CVD by 14%, while the SGLT-2i dapagliflozin did not significantly reduce the risk of MACE, possibly due to the difference in population (approximately 60% with no established ASCVD) between previous trials and strict exclusion criteria
The Precision Peptide Genetic Test ($99 add-on after your first month) provides a personalized roadmap of which peptide-driven pathways drive your weight patterns, helping you optimize non-medication strategies during your fertility window
Cody Drug supports this process by providing high-quality compounding services, including personalized glutathione preparations designed for precise daily use
However, in most cases the amount of loss is only a small fraction (less than 6%) of the RDA, and hence is of minor concern
